Annual EBITDA
-$10.23 M
-$2.73 M-36.44%
31 December 2023
Summary:
Intensity Therapeutics Common stock annual earnings before interest, taxes, depreciation & amortization is currently -$10.23 million, with the most recent change of -$2.73 million (-36.44%) on 31 December 2023. During the last 3 years, it has fallen by -$2.35 million (-29.89%). INTS annual EBITDA is now -80.30% below its all-time high of -$5.68 million, reached on 01 December 2019.INTS EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$3.51 M
+$1.46 M+29.33%
30 September 2024
Summary:
Intensity Therapeutics Common stock quarterly earnings before interest, taxes, depreciation & amortization is currently -$3.51 million, with the most recent change of +$1.46 million (+29.33%) on 30 September 2024. Over the past year, it has dropped by -$341.00 thousand (-10.75%). INTS quarterly EBITDA is now -180.37% below its all-time high of -$1.25 million, reached on 31 March 2023.INTS Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$16.26 M
-$1.18 M-7.85%
30 September 2024
Summary:
Intensity Therapeutics Common stock TTM earnings before interest, taxes, depreciation & amortization is currently -$16.26 million, with the most recent change of -$1.18 million (-7.85%) on 30 September 2024. Over the past year, it has dropped by -$6.03 million (-58.89%). INTS TTM EBITDA is now -881.05% below its all-time high of -$1.66 million, reached on 01 December 2020.INTS TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
INTS EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -10.8% | -58.9% |
| 3 y3 years | -29.9% | -54.4% | -106.4% |
| 5 y5 years | -80.3% | - | - |
INTS EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -36.4% | at low | -180.4% | +29.3% | -155.9% | at low |
| 5 y | 5 years | -80.3% | at low | -180.4% | +29.3% | -881.0% | at low |
| alltime | all time | -80.3% | at low | -180.4% | +29.3% | -881.0% | at low |
Intensity Therapeutics Common Stock EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$3.51 M(-29.3%) | -$16.26 M(+7.9%) |
| June 2024 | - | -$4.97 M(+8.0%) | -$15.07 M(+11.0%) |
| Mar 2024 | - | -$4.60 M(+45.1%) | -$13.58 M(+32.7%) |
| Dec 2023 | -$10.23 M(+36.4%) | -$3.17 M(+36.2%) | -$10.23 M(+19.9%) |
| Sept 2023 | - | -$2.33 M(-33.1%) | -$8.53 M(+7.1%) |
| June 2023 | - | -$3.48 M(+177.7%) | -$7.96 M(+25.4%) |
| Mar 2023 | - | -$1.25 M(-15.0%) | -$6.35 M(-14.3%) |
| Dec 2022 | -$7.50 M | -$1.47 M(-16.3%) | -$7.41 M(-9.8%) |
| Sept 2022 | - | -$1.76 M(-5.8%) | -$8.21 M(-4.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2022 | - | -$1.87 M(-19.1%) | -$8.59 M(-1.1%) |
| Mar 2022 | - | -$2.31 M(+1.5%) | -$8.69 M(+10.3%) |
| Dec 2021 | -$7.88 M(+26.6%) | - | - |
| Dec 2021 | - | -$2.27 M(+6.4%) | -$7.88 M(+8.5%) |
| Sept 2021 | - | -$2.14 M(+8.8%) | -$7.26 M(+41.7%) |
| June 2021 | - | -$1.96 M(+30.9%) | -$5.12 M(+62.2%) |
| Mar 2021 | - | -$1.50 M(-9.4%) | -$3.16 M(+90.6%) |
| Dec 2020 | -$6.22 M(+9.7%) | -$1.66 M | -$1.66 M |
| Dec 2019 | -$5.68 M | - | - |
FAQ
- What is Intensity Therapeutics Common stock annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Intensity Therapeutics Common stock?
- What is Intensity Therapeutics Common stock quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Intensity Therapeutics Common stock?
- What is Intensity Therapeutics Common stock quarterly EBITDA year-on-year change?
- What is Intensity Therapeutics Common stock TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Intensity Therapeutics Common stock?
- What is Intensity Therapeutics Common stock TTM EBITDA year-on-year change?
What is Intensity Therapeutics Common stock annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of INTS is -$10.23 M
What is the all time high annual EBITDA for Intensity Therapeutics Common stock?
Intensity Therapeutics Common stock all-time high annual earnings before interest, taxes, depreciation & amortization is -$5.68 M
What is Intensity Therapeutics Common stock quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of INTS is -$3.51 M
What is the all time high quarterly EBITDA for Intensity Therapeutics Common stock?
Intensity Therapeutics Common stock all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$1.25 M
What is Intensity Therapeutics Common stock quarterly EBITDA year-on-year change?
Over the past year, INTS quarterly earnings before interest, taxes, depreciation & amortization has changed by -$341.00 K (-10.75%)
What is Intensity Therapeutics Common stock TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of INTS is -$16.26 M
What is the all time high TTM EBITDA for Intensity Therapeutics Common stock?
Intensity Therapeutics Common stock all-time high TTM earnings before interest, taxes, depreciation & amortization is -$1.66 M
What is Intensity Therapeutics Common stock TTM EBITDA year-on-year change?
Over the past year, INTS TTM earnings before interest, taxes, depreciation & amortization has changed by -$6.03 M (-58.89%)